SEC Form 4 · accession 0000874015-26-000239
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
C Frank Bennett
Officer — EVP, Chief Scientific Officer
Period of report
Jul 7, 2026
Accepted (ET)
Jul 9, 2026 · 7:26 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 7, 2026 | S | 5,536 | $83.579 | D | 75,018 | D | |
| Common StockF3 | Jul 7, 2026 | J | 15,000 | $0.00 | A | 15,000 | I | by Trust |
| Common StockF1,F4 | Jul 7, 2026 | S | 15,000 | $85.462 | D | 0 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF5 | $0.00 | Jul 7, 2026 | J | 15,000 | D | — | — | Common Stock | 15,000 | 12,109 | D |
Explanation of responses
- F1Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.070 to $84.065 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3Represents a transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, of which the reporting person is the co-trustee with spouse.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.015 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- F5Restricted Stock Unit vested on January 15, 2026. Upon vesting, the restricted stock unit was paid out in whole shares of Ionis common stock.